CRVS
Corvus Pharmaceuticals Inc

6,116
Mkt Cap
$558.62M
Volume
448,635.00
52W High
$9.60
52W Low
$2.54
PE Ratio
-13.98
CRVS Fundamentals
Price
$7.48
Prev Close
$7.37
Open
$7.39
50D MA
$8.07
Beta
1.56
Avg. Volume
966,260.42
EPS (Annual)
-$1.02
P/B
7.78
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading 7.1% Higher - What's Next?
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 7.1% - Here's Why...
MarketBeat·18d ago
News Placeholder
More News
News Placeholder
Corvus Pharmaceuticals (NASDAQ:CRVS) Sets New 12-Month High - Here's What Happened
Corvus Pharmaceuticals (NASDAQ:CRVS) Sets New 12-Month High - Should You Buy...
MarketBeat·20d ago
News Placeholder
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five brokerages that are currently covering the firm, MarketBeat...
MarketBeat·24d ago
News Placeholder
Foresite Capital Management VI LLC Boosts Position in Corvus Pharmaceuticals, Inc. $CRVS
Foresite Capital Management VI LLC lifted its position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 9.5% in the 2nd quarter, according to its most recent disclosure with...
MarketBeat·30d ago
News Placeholder
BML Capital Management LLC Buys New Stake in Corvus Pharmaceuticals, Inc. $CRVS
BML Capital Management LLC bought a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with...
MarketBeat·1mo ago
News Placeholder
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Up 7.4% - Still a Buy?
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading 7.4% Higher - What's Next...
MarketBeat·1mo ago
News Placeholder
Cantor Fitzgerald Issues Positive Forecast for CRVS Earnings
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Equities researchers at Cantor Fitzgerald lifted their FY2026 EPS estimates for Corvus Pharmaceuticals in a research note issued to...
MarketBeat·2mo ago
News Placeholder
What is HC Wainwright's Estimate for CRVS FY2025 Earnings?
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Analysts at HC Wainwright upped their FY2025 EPS estimates for Corvus Pharmaceuticals in a research note issued on Wednesday, November 5th...
MarketBeat·2mo ago
News Placeholder
Wall Street Zen Upgrades Corvus Pharmaceuticals (NASDAQ:CRVS) to "Hold"
Wall Street Zen raised Corvus Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·2mo ago
News Placeholder
HC Wainwright Has Bearish Forecast for CRVS FY2028 Earnings
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Analysts at HC Wainwright reduced their FY2028 earnings per share (EPS) estimates for shares of Corvus Pharmaceuticals in a report released...
MarketBeat·2mo ago
<
1
2
...
>

Latest CRVS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.